FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220955089> ?p ?o ?g. }

• W4220955089 endingPage "101009" @default.
• W4220955089 startingPage "101009" @default.
• W4220955089 abstract "Patients with non-valvular atrial fibrillation (NVAF) need prophylactically antithrombotic therapies to reduce the risk of stroke. We hypothesized that the prognostic benefits of prophylactic antithrombotic therapies outweighed the bleeding risk among very elderly (≥85 years old) patients.We analyzed clinical characteristics and outcomes of patients with NVAF in different age groups who had received different prophylactic antithrombotic therapies. We enrolled 3895 consecutive NVAF patients in the Macau Special Administrative Region (Macau SAR) of China from January 1, 2010, to December 31, 2018. Among 3524 patients [including 1252 (35.53%) very elderly patients] who completed the entire study, 2897 (82.21%) patients had a CHA2DS2-VASc score ≥ 2, 2274 (64.53%) had HAS-BLED score < 3, and 1659 (47.08%) had both of the above. The follow-up time was 3.80 (median, interquartile range 1.89-6.56) years. The primary outcome was the first occurrence of ischemic stroke, major bleeding, clinically relevant non-major gastrointestinal bleeding (CRNM-GIB), and all-cause mortality.A total of 2012 patients (57.09%) received no antithrombotic (NAT), 665 (18.87%) received antiplatelet (AP) agents, 371 (10.53%) received vitamin K antagonist (VKA), and 476 (13.51%) received non-vitamin K antagonist oral anticoagulants (NOACs). Eventually, 610 (17.31%) patients experienced thromboembolic events, with 167 (4.74%) strokes and 483 (13.71%) transient ischemia attack (TIA)/strokes. Bleeding events occurred in 614 (17.42%) patients, with 131 (3.72%) major bleeding, 381 (10.81%) CRNM-GIB and 102 (2.89%) minor bleeding events. All-cause deaths occurred in 483 (13.71%) patients. Compared with patients receiving NAT, patients receiving NOACs and VKA had fewer strokes (hazard ratio [HR]: 0.038; 95 %CI 0.004-0.401; p = 0.006 and HR: 0.544; 95 %CI 0.307-0.965; p = 0.037, respectively), and lower all-cause mortality (HR: 0.270; 95 %CI 0.170-0.429; p < 0.001 and HR: 0.531; 95 %CI 0.373-0.756; p < 0.001, respectively). Of note, very elderly patients with NVAF receiving NOACs had fewer strokes (adjust hazard ratio [adjHR]: 0.042; 95 %CI 0.002-1.003; p = 0.050) and lower all-cause mortality (adjHR: 0.308; 95 %CI 0.158-0.601; p = 0.001). Meanwhile, despite higher CRNM-GIB events (adjHR: 1.736; 95 %CI 1.042-2.892; p = 0.034), major bleeding events (adjHR: 1.045; 95 %CI 0.366-2.979; p = 0.935) did not significantly increase. VKA neither reduced strokes (adjHR: 1.015; 95 %CI 0.529-1.948; p = 0.963), nor improved all-cause mortality (adjHR: 0.995; 95 %CI 0.641-1.542; p = 0.981) in very elderly patients with NVAF.Antithrombotic treatment (VKA and NOACs) reduces stroke and improves prognosis in patients in different age groups with NVAF. The prognostic benefits of NOACs outweigh their bleeding risks in very elderly patients with NVAF." @default.
• W4220955089 created "2022-04-03" @default.
• W4220955089 creator A5003107678 @default.
• W4220955089 creator A5009146804 @default.
• W4220955089 creator A5015565428 @default.
• W4220955089 creator A5024719785 @default.
• W4220955089 creator A5029241959 @default.
• W4220955089 creator A5029423620 @default.
• W4220955089 creator A5045597594 @default.
• W4220955089 creator A5045635523 @default.
• W4220955089 creator A5051317858 @default.
• W4220955089 creator A5071017819 @default.
• W4220955089 date "2022-06-01" @default.
• W4220955089 modified "2023-10-01" @default.
• W4220955089 title "Clinical features and outcomes of patients in different age groups with non-valvular atrial fibrillation receiving oral anticoagulants" @default.
• W4220955089 cites W2096246254 @default.
• W4220955089 cites W2097854437 @default.
• W4220955089 cites W2136489990 @default.
• W4220955089 cites W2152623033 @default.
• W4220955089 cites W2159730165 @default.
• W4220955089 cites W2162499932 @default.
• W4220955089 cites W2162508946 @default.
• W4220955089 cites W2162586165 @default.
• W4220955089 cites W2581378487 @default.
• W4220955089 cites W2606280127 @default.
• W4220955089 cites W2739440077 @default.
• W4220955089 cites W2772937227 @default.
• W4220955089 cites W2889535274 @default.
• W4220955089 cites W2902273797 @default.
• W4220955089 cites W2909682326 @default.
• W4220955089 cites W2911839715 @default.
• W4220955089 cites W2912139642 @default.
• W4220955089 cites W2924769497 @default.
• W4220955089 cites W2942762030 @default.
• W4220955089 cites W2966019694 @default.
• W4220955089 cites W2981542323 @default.
• W4220955089 cites W2997103533 @default.
• W4220955089 cites W3003141915 @default.
• W4220955089 cites W3010385357 @default.
• W4220955089 cites W3014495240 @default.
• W4220955089 cites W3024224644 @default.
• W4220955089 cites W3082179368 @default.
• W4220955089 cites W3082188176 @default.
• W4220955089 cites W3108148670 @default.
• W4220955089 cites W3110829429 @default.
• W4220955089 cites W3110909176 @default.
• W4220955089 cites W3119721107 @default.
• W4220955089 cites W3119778888 @default.
• W4220955089 cites W3163999946 @default.
• W4220955089 cites W3173443406 @default.
• W4220955089 cites W3176935996 @default.
• W4220955089 cites W3184757958 @default.
• W4220955089 cites W3213637563 @default.
• W4220955089 cites W4254457194 @default.
• W4220955089 cites W4301354657 @default.
• W4220955089 doi "https://doi.org/10.1016/j.ijcha.2022.101009" @default.
• W4220955089 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35372665" @default.
• W4220955089 hasPublicationYear "2022" @default.
• W4220955089 type Work @default.
• W4220955089 citedByCount "1" @default.
• W4220955089 countsByYear W42209550892023 @default.
• W4220955089 crossrefType "journal-article" @default.
• W4220955089 hasAuthorship W4220955089A5003107678 @default.
• W4220955089 hasAuthorship W4220955089A5009146804 @default.
• W4220955089 hasAuthorship W4220955089A5015565428 @default.
• W4220955089 hasAuthorship W4220955089A5024719785 @default.
• W4220955089 hasAuthorship W4220955089A5029241959 @default.
• W4220955089 hasAuthorship W4220955089A5029423620 @default.
• W4220955089 hasAuthorship W4220955089A5045597594 @default.
• W4220955089 hasAuthorship W4220955089A5045635523 @default.
• W4220955089 hasAuthorship W4220955089A5051317858 @default.
• W4220955089 hasAuthorship W4220955089A5071017819 @default.
• W4220955089 hasBestOaLocation W42209550891 @default.
• W4220955089 hasConcept C119060515 @default.
• W4220955089 hasConcept C126322002 @default.
• W4220955089 hasConcept C127413603 @default.
• W4220955089 hasConcept C164705383 @default.
• W4220955089 hasConcept C2776301958 @default.
• W4220955089 hasConcept C2776704044 @default.
• W4220955089 hasConcept C2777015399 @default.
• W4220955089 hasConcept C2778080469 @default.
• W4220955089 hasConcept C2778369440 @default.
• W4220955089 hasConcept C2779161974 @default.
• W4220955089 hasConcept C2780645631 @default.
• W4220955089 hasConcept C3017811039 @default.
• W4220955089 hasConcept C3020199598 @default.
• W4220955089 hasConcept C541997718 @default.
• W4220955089 hasConcept C71924100 @default.
• W4220955089 hasConcept C78519656 @default.
• W4220955089 hasConceptScore W4220955089C119060515 @default.
• W4220955089 hasConceptScore W4220955089C126322002 @default.
• W4220955089 hasConceptScore W4220955089C127413603 @default.
• W4220955089 hasConceptScore W4220955089C164705383 @default.
• W4220955089 hasConceptScore W4220955089C2776301958 @default.
• W4220955089 hasConceptScore W4220955089C2776704044 @default.
• W4220955089 hasConceptScore W4220955089C2777015399 @default.
• W4220955089 hasConceptScore W4220955089C2778080469 @default.
• W4220955089 hasConceptScore W4220955089C2778369440 @default.

• next